#1 Clinical Trials Search in Europe

Soft Paraffin And Fat Products

This article discusses the use of Soft Paraffin and Fat Products in clinical trials for treating atopic dermatitis. These products are being studied alongside other interventions to evaluate their effectiveness in managing moderate to severe cases of this skin condition in adults. The trials aim to provide valuable insights into potential new treatment options for patients struggling with atopic dermatitis.

Table of Contents

Introduction to SOFT PARAFFIN AND FAT PRODUCTS

SOFT PARAFFIN AND FAT PRODUCTS is a medical treatment currently being studied for its potential effectiveness in treating moderate-to-severe atopic dermatitis in adults[1]. This treatment belongs to a category of products known as emollients, which are designed to moisturize and protect the skin[1].

Understanding Atopic Dermatitis

Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by dry, itchy, and inflamed skin[1]. It can significantly impact a person’s quality of life, causing discomfort and sometimes leading to skin infections. The condition is considered moderate-to-severe when it covers a large area of the body and doesn’t respond well to standard treatments.

Clinical Trial Overview

A clinical trial is currently underway to evaluate the effectiveness and safety of SOFT PARAFFIN AND FAT PRODUCTS in treating adults with moderate-to-severe atopic dermatitis[1]. The study, identified as J4E-MC-IMMB and J4E-MC-FR01, is a Phase 2 trial, which means it’s testing the treatment in a larger group of people to see how well it works and to further assess its safety.

The main goal of this study is to compare the efficacy of the treatment (referred to as LY3454738 in the trial) versus a placebo. The researchers will measure success using a scale called the Eczema Area and Severity Index (EASI). Specifically, they’re looking at the percentage of participants who achieve a 75% improvement in their EASI score, known as EASI-75[1].

Eligibility Criteria

To participate in this study, patients must meet certain criteria. These include:

  • Having active atopic dermatitis for over a year
  • Having an EASI score of 12 or higher at the first dosing visit (This score helps measure the severity of eczema)
  • Having a vIGA-AD score of 3 or higher at the first dosing visit (This is another measure of eczema severity)
  • Having at least 10% of body surface area (BSA) affected by eczema
  • Showing little improvement with topical medicines

There are also conditions that would exclude a person from participating, such as:

  • Recent skin infections requiring treatment with topical corticosteroids
  • A history of psoriasis (another type of skin condition)
  • Certain other infections like Hepatitis B or C
  • Known allergies to the study drug or its components

Potential Benefits and Considerations

If proven effective, SOFT PARAFFIN AND FAT PRODUCTS could offer a new treatment option for people with moderate-to-severe atopic dermatitis who haven’t responded well to other treatments[1]. However, it’s important to note that as this is still in the clinical trial phase, the full benefits and potential side effects are not yet fully known.

Administration and Usage

SOFT PARAFFIN AND FAT PRODUCTS is designed to be applied topically, which means it’s spread directly onto the skin[1]. This method of application is generally easy for patients to use at home and can be less invasive than some other treatments for atopic dermatitis.

The exact dosage and frequency of application are likely being determined as part of the clinical trial. It’s crucial that patients follow the instructions provided by their healthcare provider or the study coordinators when using this or any medical treatment.

Aspect Details
Study Drug Soft Paraffin and Fat Products (alongside LY3454738)
Condition Studied Moderate to Severe Atopic Dermatitis
Study Type Phase 2, Randomized, Double-Blind, Placebo-Controlled
Duration 52 weeks
Primary Outcome Percentage of participants achieving EASI-75
Key Inclusion Criteria EASI score ≥ 12, vIGA-AD score ≥3, ≥10% BSA involvement
Key Exclusion Criteria Prior skin infections, history of psoriasis, other infections
Route of Administration Topical

FAQ

  • What is the main purpose of the clinical trial using Soft Paraffin and Fat Products? The main purpose of the clinical trial is to evaluate the efficacy and safety of a new drug called LY3454738, along with other interventions including Soft Paraffin and Fat Products, in treating moderate to severe atopic dermatitis in adults.
  • Who can participate in this clinical trial? Participants must be adults with moderate to severe atopic dermatitis that has been active for over a year. They should have an EASI score ≥ 12, a vIGA-AD score ≥3, and at least 10% of body surface area involvement. Additionally, they should have shown little improvement with topical medicines.
  • What is the primary outcome measure of the trial? The primary outcome measure is the percentage of participants achieving an Eczema Area and Severity Index (EASI) 75, which indicates a 75% improvement in their condition.
  • How long does the clinical trial last? The clinical trial is designed as a 52-week study to evaluate the long-term efficacy and safety of the treatments.
  • Are there any specific conditions that would exclude someone from participating? Yes, exclusion criteria include prior skin infections requiring treatment with topical corticosteroids, a history of psoriasis, other infections such as Hepatitis B or C, and known allergies to the study drug or its components.

Ongoing Clinical Trials on Soft Paraffin And Fat Products

  • Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Hungary Italy Poland

Glossary

  • Atopic Dermatitis: A chronic inflammatory skin condition characterized by itchy, red, and dry skin. It's also known as eczema.
  • EASI (Eczema Area and Severity Index): A tool used to measure the extent and severity of atopic dermatitis. EASI-75 indicates a 75% improvement in the condition.
  • vIGA-AD (Validated Investigator Global Assessment for Atopic Dermatitis): A scale used by healthcare professionals to assess the overall severity of atopic dermatitis.
  • BSA (Body Surface Area): A measurement of the percentage of the body affected by a skin condition.
  • Topical: Applied directly to the skin.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Phase 2 Clinical Trial: A stage of drug testing where the effectiveness and safety of a new treatment are evaluated in a larger group of patients.

References

  1. http://clinicaltrials.eu/trial/study-of-ly3454738-for-treating-moderate-to-severe-atopic-dermatitis-in-adults/